TABLE 4.
Associations Between Cumulative Statin Use and Health Outcomes, 2006-2010
| Statin Use | Model 1a HR (95% CI) | Model 2b HR (95% CI) |
|---|---|---|
| All-cause mortality | n = 6,975 | |
| Number of events (%) | 738 (10.6) | |
| Cumulative statin | ||
| ≤ 120 | 1.00 (referent) | 1.00 (referent) |
| 121-240 | 1.39 (1.09-1.76) | 1.37 (1.08-1.74) |
| 241-360 | 1.27 (1.01-1.61) | 1.25 (0.99-1.58) |
| > 360 | 1.22 (1.00-1.48) | 1.19 (0.98-1.45) |
| Cardiovascular deaths | n = 6,855 | |
| Number of events (%) | 196 (2.9) | |
| Cumulative statin | ||
| ≤ 120 | 1.00 (referent) | 1.00 (referent) |
| 121-240 | 1.13 (0.74-1.71) | 1.11 (0.73-1.68) |
| 241-360 | 0.79 (0.50-1.25) | 0.75 (0.47-1.18) |
| > 360 | 0.71 (0.50-1.02) | 0.66 (0.46-0.94) |
| Incident MI | n = 6,777 | |
| Number of events (%) | 245 (3.6) | |
| Cumulative statin | ||
| ≤ 120 | 1.00 (referent) | 1.00 (referent) |
| 121-240 | 0.63 (0.42-0.93) | 0.63 (0.43-0.94) |
| 241-360 | 0.64 (0.44-0.94) | 0.64 (0.44-0.93) |
| > 360 | 0.37 (0.27-0.51) | 0.36 (0.26-0.50) |
| Incident stroke | n = 6,732 | |
| Number of events (%) | 290 (4.3) | |
| Cumulative statin | ||
| ≤ 120 | 1.00 (referent) | 1.00 (referent) |
| 121-240 | 0.88 (0.62-1.25) | 0.88 (0.62-1.25) |
| 241-360 | 0.67 (0.47-0.97) | 0.67 (0.47-0.96) |
| > 360 | 0.48 (0.37-0.65) | 0.48 (0.36-0.64) |
| Total Costs | Cost Ratios (95% CI) | Cost Ratios (95% CI) |
| Cumulative statin | ||
| ≤ 120 | 1.00 (referent) | 1.00 (referent) |
| 121-240 | 1.02 (0.95-1.10) | 1.02 (0.94-1.10) |
| 241-360 | 0.95 (0.88-1.01) | 0.94 (0.88-1.01) |
| > 360 | 1.02 (0.96-1.09) | 1.01 (0.95-1.08) |
a Model 1: adjusted for gender, atrial fibrillation, hypertension, chronic pulmonary disease, diabetes duration, and treatment intensity.
b Model 2: Model 1, plus adjusted for MI, stroke, congestive heart failure, or coronary artery disease, 1997-2005.
CI = confidence interval; HR = hazard ratio; MI = myocardial infarction.